Milestone Scientific (MLSS)
XASE:MLSS
Want to see MLSS full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a cautiously positive outlook: management delivered meaningful expense reductions (>$1.3M, >30% YoY) and materially narrowed operating and net losses (both improved ~58%), while early traction in CompuFlo (medical revenue up >100% and roughly $108k in Q1), strong digital lead generation (152 leads), >50 reimbursement claims submitted, expansion of distributor and ambassador programs, and a $2.15M financing bolster the growth case. Key near-term risks remain—flat overall revenue for the quarter, a $200k shipping disruption, modest gross margin decline, CompuFlo's small absolute revenue base, and dependence on Medicare/MAC reimbursement timing and utilization to unlock nonlinear growth. Given that the positive operational improvements, financing, and early commercial traction outweigh the execution and reimbursement risks at this stage, the overall sentiment is constructive but cautious.Company Guidance
Operating Expense Reduction
Reduced operating expenses by approximately $1.3 million, representing more than a 30% year-over-year decrease, contributing to significantly narrowed losses.
Improved Profitability Metrics
Operating loss improved to $828,000, a 58% improvement (about $1.2 million) versus the prior-year quarter; net loss narrowed to $840,000, also a 58% improvement (about $1.2 million).
Stable Revenue Base
Total revenue was approximately $2.2 million for the quarter, essentially flat year-over-year, demonstrating resilience despite regional shipping disruptions.
Strong Gross Margin
Gross profit of $1.56 million with gross margin remaining robust at 72.3% (down slightly from 73.8% prior-year period).
CompuFlo Medical Traction
Medical (CompuFlo) revenue more than doubled year-over-year from a small base, generating about $108,000 in Q1, indicating early-stage adoption and momentum.
Demand and Lead Generation
Digital marketing campaign for CompuFlo produced 152 leads (roughly 20–30 new leads per week), and the company reports early rapid purchase decisions with some orders converting within a week.
Clinical and Reimbursement Progress
Over 8 physician partners actively engaged and 6 pending in the CompuFlo Advisor Program; over 50 claims submitted across three MACs (Novitas, Palmetto, First Coast), and a dedicated reimbursement infrastructure and call center in place to support Medicare engagement.
Commercial Expansion
Onboarded distribution partners (management cited 7 new partners; later referenced 8 distribution partners), representing an expanded field footprint (estimated 20–30 salespeople across distributors) with quotas and initial orders received.
Dental Ambassador Program Early Results
Ambassador program expansion produced 173 applications, 73 active ambassadors, 25 new demos and multiple new sales; company hiring to scale program support and expects contribution later in the year.
Balance Sheet Strengthening
Completed a $2.15 million financing (PIPE) subsequent to quarter-end, providing additional flexibility to invest in sales, inventory and digital marketing while maintaining disciplined capital allocation.
Reaffirmed Guidance and Path to Breakeven
Reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million (double-digit year-over-year growth) and reiterated goal to reach cash flow breakeven in early 2027 through structural cost reductions and revenue growth.
International Registration Progress
Pursuing new product registrations in key markets (India and Mexico expected within the next quarter; Japan targeted around September) that could meaningfully expand addressable markets by Q4 if approved.
MLSS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MLSS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $0.35 | $0.34 | -4.29% |
Mar 31, 2026 | $0.29 | $0.30 | +3.47% |
Nov 13, 2025 | $0.38 | $0.33 | -12.93% |
Aug 14, 2025 | $0.58 | $0.65 | +12.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Milestone Scientific (MLSS) report earnings?
Milestone Scientific (MLSS) is schdueled to report earning on Aug 18, 2026, TBA (Confirmed).
What is Milestone Scientific (MLSS) earnings time?
Milestone Scientific (MLSS) earnings time is at Aug 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLSS EPS forecast?
MLSS EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.